Drugs / Medium-Chain Triglycerides
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SMOFLIPID 20% | — | 2016-07-13 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02201368 | Nov 2009 → Mar 2010 | long chain fatty acids, defect in transport of | Maria Luz Couce Pico | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06376266 | Oct → Dec 2023 | muscular atrophy | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Medium-Chain Triglycerides | “The intervention group will receive a daily supplement of branched-chain amino acids combined with medium-chain triglycerides, while the control group will be given...” NCT06376266 ↗1“MCT (Medium-Chain Triglycerides)” NCT02201368 ↗ |
| Known as | MCT | “MCT (Medium-Chain Triglycerides)” NCT02201368 ↗ |